Recently, PHARMAC undertook an unfortunate experiment on asthma sufferers when it fundamentally changed its funding support for reliever medications. Ventolin metered dose inhaler (MDI), the backbone of asthma relief for over 30 years, was dropped in favour of Salamol, a post-patent salbutamol in a device which, within the first few weeks of use, has been found to be ineffective by many patients, and thus potentially dangerous. PHARMAC has agreed to reconsider its decision, but how was this decision reached in the first place?
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
pharmac ventolin
4
ventolin zealand
4
zealand pharmac
4
pharmac undertook
4
undertook unfortunate
4
unfortunate experiment
4
experiment asthma
4
asthma sufferers
4
sufferers fundamentally
4
fundamentally changed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!